Applying a genetic risk score for prostate cancer to men with lower urinary tract symptoms in primary care to predict prostate cancer diagnosis: a cohort study in the UK Biobank
dc.contributor.author | Green, HD | |
dc.contributor.author | Merriel, SWD | |
dc.contributor.author | Oram, RA | |
dc.contributor.author | Ruth, KS | |
dc.contributor.author | Tyrrell, J | |
dc.contributor.author | Jones, SE | |
dc.contributor.author | Thirwell, C | |
dc.contributor.author | Weedon, MN | |
dc.contributor.author | Bailey, SER | |
dc.date.accessioned | 2022-07-08T12:06:52Z | |
dc.date.issued | 2022-08-18 | |
dc.date.updated | 2022-07-08T11:46:31Z | |
dc.description.abstract | Background Prostate cancer is highly heritable, with >250 common variants associated in genome-wide association studies. It commonly presents with non-specific lower urinary tract symptoms that are frequently associated with benign conditions. Methods Cohort study using UK Biobank data linked to primary care records. Participants were men with a record showing a general practice consultation for a lower urinary tract symptom. The outcome measure was prostate cancer diagnosis within two years of consultation. The predictor was a genetic risk score of 269 genetic variants for prostate cancer. Results A genetic risk score (GRS) is associated with prostate cancer in symptomatic men (OR per SD increase=2.12 [1.86 to 2.41] p=3.5e-30). An integrated risk model including age and GRS applied to symptomatic men predicted prostate cancer (AUC 0.768 [0.739 to 0.796]). Prostate cancer incidence was 8.1% (6.7 to 9.7) in the highest risk quintile. In the lowest quintile, prostate cancer incidence was <1%. Conclusions This study is the first to apply GRS in primary care to improve the triage of symptomatic patients. Men with the lowest genetic risk of developing prostate cancer could safely avoid invasive investigation, whilst those identified with the greatest risk could be fast-tracked for further investigation. These results show that a GRS has potential application to improve the diagnostic pathway of symptomatic patients in primary care. | en_GB |
dc.description.sponsorship | Higgins family | en_GB |
dc.identifier.citation | Published online 18 August 2022 | en_GB |
dc.identifier.doi | 10.1038/s41416-022-01918-z | |
dc.identifier.uri | http://hdl.handle.net/10871/130194 | |
dc.identifier | ORCID: 0000-0003-0020-4778 (Bailey, Sarah) | |
dc.language.iso | en | en_GB |
dc.publisher | Springer Nature / Cancer Research UK | en_GB |
dc.relation.url | https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access | en_GB |
dc.relation.url | https://github.com/hdg204/ProstateCancer | en_GB |
dc.rights | © The Author(s) 2022. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ | |
dc.title | Applying a genetic risk score for prostate cancer to men with lower urinary tract symptoms in primary care to predict prostate cancer diagnosis: a cohort study in the UK Biobank | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2022-07-08T12:06:52Z | |
dc.identifier.issn | 0007-0920 | |
dc.description | This is the final version. Available on open access from Springer Nature via the DOI in this record | en_GB |
dc.description | Data availability: All data in this project was part of the UK Biobank resource and was accessed under application number 74981. Information on how to access the UK Biobank can be found at https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access | en_GB |
dc.description | Code availability: All code used to generate results for this study can be found at the author’s Github page: https://github.com/hdg204/ProstateCancer | en_GB |
dc.identifier.eissn | 1532-1827 | |
dc.identifier.journal | British Journal of Cancer | en_GB |
dc.relation.ispartof | British Journal of Cancer | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | en_GB |
dcterms.dateAccepted | 2022-07-12 | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2022-07-12 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2022-07-08T11:46:33Z | |
refterms.versionFCD | AM | |
refterms.dateFOA | 2022-09-15T14:04:17Z | |
refterms.panel | A | en_GB |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © The Author(s) 2022. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/